Boston Scientific announced that the CHAMPION‑AF global clinical trial met all primary and secondary safety and efficacy endpoints for its WATCHMAN FLX left‑atrial appendage closure device. The 3,000‑patient study, which followed participants for 36 months, demonstrated that WATCHMAN FLX was statistically non‑inferior to non‑vitamin K antagonist oral anticoagulants for major bleeding (10.9% vs. 19.0%) and superior for a composite safety and efficacy endpoint (15.1% vs. 21.8%). The device achieved a 99 % procedural success rate and produced a 5.7% stroke, cardiovascular death, or systemic embolism rate versus 4.8% for NOACs, confirming its robust performance across a broad patient population.
The trial’s success could reposition WATCHMAN FLX from a second‑line option to a first‑line therapy for stroke risk reduction in patients with non‑valvular atrial fibrillation. If adopted as a first‑line treatment, the device could expand Boston Scientific’s addressable market from an estimated 5 million to 20 million patients worldwide, providing a significant upside for the company’s cardiovascular segment and reinforcing its competitive position against NOACs and other left‑atrial appendage closure devices.
"The success of the landmark CHAMPION‑AF trial represents a meaningful milestone that will undoubtedly transform the treatment approach to stroke risk reduction in a broader population of patients who historically have needed to rely on medication," said Martin Leon, M.D., study co‑chair. "These results should give clinicians confidence in the potential of the WATCHMAN FLX device to become a first‑line treatment option for reducing the risk of stroke for a rapidly growing number of patients with AF."
Analysts have maintained buy ratings on Boston Scientific, with RBC Capital Markets keeping an outperformance rating. The trial results are a key driver of analyst sentiment, but concerns about the company’s electrophysiology segment and guidance have weighed on investor sentiment. Nonetheless, the positive data reinforce confidence in the WATCHMAN FLX platform’s future growth potential.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.